Therapeutic implications of orally delivered immunomodulatory oligonucleotides
- PMID: 25633172
- PMCID: PMC4445629
- DOI: 10.1038/mt.2014.251
Therapeutic implications of orally delivered immunomodulatory oligonucleotides
Comment on
-
Inhibitory/suppressive oligodeoxynucleotide nanocapsules as simple oral delivery devices for preventing atopic dermatitis in mice.Mol Ther. 2015 Feb;23(2):297-309. doi: 10.1038/mt.2014.239. Epub 2014 Dec 15. Mol Ther. 2015. PMID: 25502904 Free PMC article.
References
-
- Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006;5:471–484. - PubMed
-
- Klinman DM, Tross D, Klaschik S, Shirota H., and, Sato T. Therapeutic applications and mechanisms underlying the activity of immunosuppressive oligonucleotides. Ann NY Acad Sci. 2009;1175:80–88. - PubMed
-
- Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004;4:249–258. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
